Literature DB >> 20467430

Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?

Rajiv Agarwal1.   

Abstract

Vitamin D receptor agonists (VDRAs) inhibit the renin-angiotensin system (RAS) and reduce podocyte loss and fibrosis over and above RAS blockade. Several studies in humans show that VDRAs are antiproteinuric and have the potential to delay the progression of renal disease. Whether VDRAs will accomplish this goal among proteinuric patients with chronic kidney disease needs to be tested in randomized controlled trials.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20467430     DOI： 10.1038/ki.2010.77

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Renoprotective effects of Vitamin D and renin-angiotensin system.

Authors:  A Koroshi; A Idrizi
Journal:  Hippokratia       Date:  2011-10       Impact factor: 0.471

Review 2.  The podocyte as a target for therapies--new and old.

Authors:  Peter W Mathieson
Journal:  Nat Rev Nephrol       Date:  2011-11-01       Impact factor: 28.314

3.  Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study.

Authors:  Luca De Nicola; Giuseppe Conte; Domenico Russo; Antonio Gorini; Roberto Minutolo
Journal:  BMC Nephrol       Date:  2012-11-20       Impact factor: 2.388

Review 4.  Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system.

Authors:  Domenico Santoro; Daniela Caccamo; Silvia Lucisano; Michele Buemi; Katerina Sebekova; Daniel Teta; Luca De Nicola
Journal:  Biomed Res Int       Date:  2015-04-27       Impact factor: 3.411

5.  Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.

Authors:  Thomas Larsen; Frank H Mose; Jesper N Bech; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2013-07-26       Impact factor: 2.388

6.  COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?

Authors:  Ruth H Arnold
Journal:  Heart Lung Circ       Date:  2020-05-25       Impact factor: 2.975

Review 7.  The Role of the Renin-Angiotensin System and Vitamin D in Keloid Disorder-A Review.

Authors:  Ethan J Kilmister; Claudia Paterson; Helen D Brasch; Paul F Davis; Swee T Tan
Journal:  Front Surg       Date:  2019-11-26

8.  Evaluating hormonal mechanisms of vitamin D receptor agonist therapy in diabetic kidney disease: the VALIDATE-D study.

Authors:  Jenifer M Brown; Kristina Secinaro; Jonathan S Williams; Anand Vaidya
Journal:  BMC Endocr Disord       Date:  2013-08-23       Impact factor: 2.763

Review 9.  Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion.

Authors:  Sandro Giannini; Sandro Mazzaferro; Salvatore Minisola; Luca De Nicola; Maurizio Rossini; Mario Cozzolino
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.